Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29842346 | 1.00 | KMT2A (0.66) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL10460872 | 0.95 | KMT2A (0.64) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL10461500 | 0.94 | MAOB (0.64) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL10459166 | 0.94 | MAOB (0.64) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL1544858 | 0.94 | KMT2A (0.62) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL6856717 | 0.92 | KMT2A (0.76) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL4938004 | 0.90 | KMT2A (0.54) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL4001162 | 0.88 | KMT2A (0.66) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL1545176 | 0.88 | PRSS1 (0.55) | KMT2AMAOBMEN1PRSS1TSHR | |
| SCHEMBL1545237 | 0.88 | TSHR (0.69) | PRSS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261308-A1 | ONE-POT PROCESS FOR THE SYNTHESIS OF ILOPERIDONE | PROCOS. S.p.A. (IT) | 2013-10-03 | — | — | US | claimed |
| EP-2644608-A1 | One-pot process for the synthesis of iloperidone | Procos S.p.A. (IT) | 2013-10-02 | — | — | EP | claimed |
| US-20130190501-A1 | PROCESSES FOR THE PREPARATION OF 4'-[3-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO]PROPOXY]-3'-METHOXYACETOPHENONE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-07-25 | — | — | US | claimed |
| WO-2012153341-A1 | A PROCESS FOR THE PREPARATION OF ILOPERIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ARCH PHARMALABS LIMITED (IN) | 2012-11-15 | — | — | WO | claimed |
| WO-2012063269-A2 | PROCESS FOR PREPARING ILOPERIDONE | CADILA HEALTHCARE LIMITED (IN) | 2012-05-18 | — | — | WO | claimed |
| CN-118146194-A | Novel quinoline compound containing 6-oxo-1-substituted phenyl-1, 6-dihydropyridazine-3-carboxamide and application thereof | 辽宁大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-111646940-B | Preparation method of bosutinib intermediate | 鲁南制药集团股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117343046-A | Novel 3-oxo-4-substituted aryl-3, 4-dihydropyrazine-2-carboxamide compound and application thereof | 辽宁大学 | 2024-01-05 | — | — | CN | disclosed |
| CN-111440177-B | Substituted pyrazolo [1,5-a ] pyrimidine compound and preparation method and application thereof | 辽宁大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-111646939-A | Preparation method of bosutinib | 鲁南制药集团股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111646940-A | Preparation method of bosutinib intermediate | 鲁南制药集团股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-111440177-A | Novel substituted pyrazolo [1,5-a ] pyrimidine compound and preparation method and application thereof | 辽宁大学 | 2020-07-24 | — | — | CN | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | disclosed |
| US-4366162-A | DEPRESSANT, PSYCHOLOGICAL DISORDERS | AB FERROSAN (SE) | 1982-12-28 | — | — | US | disclosed |
| US-4139620-A | HYPOTENSIVE AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4096331-A | HYPOTENSIVE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1978-06-20 | — | — | US | disclosed |
| US-4032642-A | SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-06-28 | — | — | US | disclosed |
| US-3956296-A | ANTIINFLAMMATORY, SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190501-A1 | PROCESSES FOR THE PREPARATION OF 4'-[3-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO]PROPOXY]-3'-METHOXYACETOPHENONE AND INTERMEDIATES THEREOF | CYP4B1, CYP4X1, CYP3A4 | KMT2A 1306/4885MAOB 175/4885MEN1 2135/4885 |
| US-20130261308-A1 | ONE-POT PROCESS FOR THE SYNTHESIS OF ILOPERIDONE | IL2, IL1A, IL4 | KMT2A 2900/4885MAOB 1991/4885MEN1 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.